Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open Label, Cyclosporine Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Zuberitamab Injection (HS006) in Patients With Primary Membranous Nephropathy

NCT06642909 is registered in ClinicalTrials.gov with BioRay Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06642909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06642909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open Label, Cyclosporine Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Zuberitamab Injection (HS006) in Patients With Primary Membranous Nephropathy
Lead sponsor
BioRay Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 13, 2024
Completion date
May 10, 2027
Enrollment
135 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary membranous nephropathy